Find out more about the current research focuses at KCAS Bioanalytical & Biomarker Services and how the industry has evolved over the last 5–10 years in this interview with John Bucksath (KCAS).
Types of anti-drug antibody regulated methods validated in the last 12 months at KCAS Bioanalytical & Biomarker Services
Find out more about the types of Anti-Drug Antibody (ADA) regulated methods validated in the last 12 months at KCAS Bioanalytical & Biomarker Services.
Find out more an electrochemiluminescent bridging immunogenicity assay used to measure anti-drug antibodies in human serum using an acid dissociation step in this poster from KCAS Bioanalytical & Biomarker Services (KS, USA).
Webinar available to view on demand. In this free panel discussion, our experts will provide insights into their own research with immunogenicity including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field.
Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.
In this Spotlight interview, Franklin Spriggs (KCAS; KS, USA) explains his interest in biomarkers and introduces the technologies and techniques utilized and offered by KCAS.
Available to view on demand. We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on new technology integration in the field of bioanalysis.
KCAS has invested time and resources to qualify a number of multi-parameter immunophenotyping panels which can be utilized “off the shelf” or customized to meet our client’s particular needs.
Flow cytometric immunophenotyping of PBMCs and quantification of cytokine production from patients in a peptide vaccine study
KCAS, LLC optimized a primary and secondary stimulation assay of Peripheral Blood Mononuclear Cell (PBMC)
samples from a clinical trial in order to characterize the immune response to a multi-valent peptide vaccine. In partnership with our pharmaceutical sponsor, an agreed upon set of samples were tested by KCAS, LLC to optimize a culture method, culture time course, stimulation, and re-stimulation. These samples were also used to optimize surface and intracellular staining of the following panel: CD45, CD3 CD8, PD1, CCR7, IFNγ, TNFα, IL-2 and viability dye. Upon review of the initial optimized method, the full cohort of patient samples were cultured, treated, stained, and analyzed.
The facts, frustrations and future hopes for immuno-oncology: a podcast with Dr Dominic Warrino (KCAS)
As part of our focus, we present this podcast where Dr Dominic Warrino discusses how immuno-oncology fits into the bioanalytical field and the technologies involved.